Sangamo Therapeutics Statistics
Total Valuation
SGMO has a market cap or net worth of $82.40 million. The enterprise value is $57.89 million.
| Market Cap | 82.40M |
| Enterprise Value | 57.89M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SGMO has 207.51 million shares outstanding. The number of shares has increased by 6.60% in one year.
| Shares Outstanding | 207.51M |
| Shares Change (YoY) | +6.60% |
| Shares Change (QoQ) | +1.51% |
| Owned by Insiders (%) | 7.73% |
| Owned by Institutions (%) | 50.81% |
| Float | 170.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.39 |
| Forward PS | 2.17 |
| PB Ratio | 1.45 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.71, with a Debt / Equity ratio of 0.54.
| Current Ratio | 1.71 |
| Quick Ratio | 1.39 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -258.20% and return on invested capital (ROIC) is -392.58%.
| Return on Equity (ROE) | -258.20% |
| Return on Assets (ROA) | -156.40% |
| Return on Capital (ROIC) | -392.58% |
| Revenue Per Employee | $46,311 |
| Profits Per Employee | -$810,007 |
| Employee Count | 405 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.89% in the last 52 weeks. The beta is 1.23, so SGMO's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -72.89% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 0.56 |
| Relative Strength Index (RSI) | 44.19 |
| Average Volume (20 Days) | 3,118,181 |
Short Selling Information
The latest short interest is 15.51 million, so 7.47% of the outstanding shares have been sold short.
| Short Interest | 15.51M |
| Short Previous Month | 13.80M |
| Short % of Shares Out | 7.47% |
| Short % of Float | 9.07% |
| Short Ratio (days to cover) | 5.58 |
Income Statement
In the last 12 months, SGMO had revenue of $18.76 million and -$328.05 million in losses. Loss per share was -$1.86.
| Revenue | 18.76M |
| Gross Profit | 18.76M |
| Operating Income | -343.57M |
| Pretax Income | -333.22M |
| Net Income | -328.05M |
| EBITDA | -314.08M |
| EBIT | -333.22M |
| Loss Per Share | -$1.86 |
Balance Sheet
The company has $55.33 million in cash and $30.82 million in debt, giving a net cash position of $24.52 million or $0.12 per share.
| Cash & Cash Equivalents | 55.33M |
| Total Debt | 30.82M |
| Net Cash | 24.52M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 56.70M |
| Book Value Per Share | 0.27 |
| Working Capital | 28.39M |
Cash Flow
In the last 12 months, operating cash flow was -$207.21 million and capital expenditures -$10.96 million, giving a free cash flow of -$218.16 million.
| Operating Cash Flow | -207.21M |
| Capital Expenditures | -10.96M |
| Free Cash Flow | -218.16M |
| FCF Per Share | -$1.21 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,831.76% and -1,749.06%.
| Gross Margin | 100.00% |
| Operating Margin | -1,831.76% |
| Pretax Margin | -1,776.61% |
| Profit Margin | -1,749.06% |
| EBITDA Margin | -1,674.58% |
| EBIT Margin | -1,776.61% |
| FCF Margin | -1,163.15% |
Dividends & Yields
SGMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.60% |
| Shareholder Yield | -6.60% |
| Earnings Yield | -398.11% |
| FCF Yield | -264.75% |
Analyst Forecast
The average price target for SGMO is $5.17, which is 1,201.94% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.17 |
| Price Target Difference | 1,201.94% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 13.92% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SGMO has an Altman Z-Score of -23.23 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.23 |
| Piotroski F-Score | 2 |